YHO-13177

reverses BCRP/ABCG2-mediated drug resistance; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Pancreatic Neoplasms (Pancreatic Cancer) 07/01/2011 - "In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. "
2.	Neoplasms (Cancer) 07/01/2011 - "These findings suggest that YHO-13351, a prodrug of YHO-13177, could be clinically useful for reversing BCRP-mediated drug resistance in cancer chemotherapy."
3.	Lung Neoplasms (Lung Cancer) 07/01/2011 - "In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. " 07/01/2011 - "YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. "
4.	Colonic Neoplasms (Colon Cancer) 07/01/2011 - "YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. "

1.	Drug Therapy (Chemotherapy)